Abstract 2700: Sulindac reverses an immunosuppressive tumor microenvironment associated with metastatic mammary tumors in obese mice

Autor: Andrea Walens, Shannon B. McDonell, Lydia K. Eisenbeis, Stephen D. Hursting, Alyssa J. Cozzo
Rok vydání: 2021
Předmět:
Zdroj: Cancer Research. 81:2700-2700
ISSN: 1538-7445
0008-5472
DOI: 10.1158/1538-7445.am2021-2700
Popis: Obesity is an established risk factor for several breast cancer (BC) subtypes. Obese BC patients also show poorer response to therapy, increased metastases, and increased mortality. While high levels of inflammation are thought to be a driver for BC metastasis, it is unknown how chronic exposure to low levels of obesity-associated inflammation contributes to BC progression and metastasis. We previously showed that treatment with the non-steroidal anti-inflammatory drug (NSAID) Sulindac (140 ppm mixed into control [10% kcal/fat] or diet induced obesity [DIO, 60% kcal/fat] diets) offset both the pro-growth and pro-metastatic effects of obesity on BC using three different mouse models of metastatic BC - basal-like E0771, and claudin-low metM-Wntlung and metM-Wntliver. To determine the effect of Sulindac treatment on the tumor microenvironment, we conducted gene expression microarray analysis on tumors from mice in all four diet groups (Control, Control+Sulindac, DIO, and DIO+Sulindac). Ingenuity Pathway Analysis revealed significant decreases (q This research was supported by R35CA197627 to S.D. Hursting and T32LM012420 and F30CA225142 to S.B. McDonell. Citation Format: Shannon B. McDonell, Lydia K. Eisenbeis, Andrea N. Walens, Alyssa J. Cozzo, Stephen D. Hursting. Sulindac reverses an immunosuppressive tumor microenvironment associated with metastatic mammary tumors in obese mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2700.
Databáze: OpenAIRE
Externí odkaz: